Does Rallies track congressional trades in CHRS?

Yes. Rallies tracks politician and congressional stock disclosures for CHRS, including reported purchases, sales, dates, owners, and trade amounts when available.

Is CHRS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CHRS. It does not provide personalized investment advice.

CHRS (Coherus Oncology, Inc. Common Stock) Stock Analysis - Politician Trades

Coherus Oncology, Inc. Common Stock (CHRS) is a publicly traded Healthcare sector company. As of May 21, 2026, CHRS trades at $1.52 with a market cap of $229.83M and a P/E ratio of 0.92. CHRS moved +2.36% today. Year to date, CHRS is +4.86%; over the trailing twelve months it is +85.03%. Its 52-week range spans $0.66 to $2.62. Analyst consensus is strong buy with an average price target of $8.25. Rallies surfaces CHRS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded CHRS stock?

Rallies tracks politician and congressional stock disclosures for CHRS, including purchases, sales, transaction dates, owners, and reported trade amounts when available.

CHRS Key Metrics

Key financial metrics for CHRS
Metric	Value
Price	$1.52
Market Cap	$229.83M
P/E Ratio	0.92
EPS	$1.64
Dividend Yield	0.00%
52-Week High	$2.62
52-Week Low	$0.66
Volume	71
Avg Volume	0
Revenue (TTM)	$46.88M
Net Income	$186.27M
Gross Margin	68.06%

Latest CHRS News

Coherus Oncology Q1 Sales Jump 61% to $11.8M, Raises $53.6M — May 11, 2026
Coherus Oncology Posts -153.12% ROIC Versus 11.27% WACC — Mar 25, 2026
Coherus Oncology’s Q4 Loss of $0.34 Wide of Estimates, Revenues Fall 76% — Mar 9, 2026
LOQTORZI Sales Double to $40.8M as Debt Plummets 90% to $38.8M — Mar 9, 2026
Coherus Oncology Cuts Debt 90%, Eyes $30M Quarterly LOQTORZI Run Rate — Mar 8, 2026

Recent CHRS Insider Trades

Wahlstrom Mats sold 99.99K (~$73.88K) on May 23, 2025.

CHRS Analyst Consensus

5 analysts cover CHRS: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.25.

Common questions about CHRS

Which politicians traded CHRS stock?: Rallies tracks politician and congressional stock disclosures for CHRS, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
Does Rallies track congressional trades in CHRS?: Yes. Rallies tracks politician and congressional stock disclosures for CHRS, including reported purchases, sales, dates, owners, and trade amounts when available.
Is CHRS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CHRS. It does not provide personalized investment advice.